 |
|
New Approach for Treating Recurrent Prostate Cancer on the Horizon
June 16, 2009New form of radiotherapy could revolutionize treatment for recurrent prostate cancer, say researchers at SNM's 56th Annual Meeting
TORONTO-A new study shows that an alpha-particle emitting radiopeptide-radioactive material bound to a synthetic peptide, a component of protein-is effective for treating prostate cancer in mice, according to researchers at SNM's 56th Annual Meeting in Toronto. The results could eventually result in a significant breakthrough in prostate cancer treatment, especially for patients whose cancer recurs after the prostate is removed.
"Our study shows that this novel form of treatment has the potential to target and destroy cancer cells with minimal damage to surrounding healthy tissue," said Damian Wild, University Hospital Basel, Basel, Switzerland, lead author of the study. "Eventually, this therapy could give hope to some of the hardest-to-treat prostate cancer patients and also could be applied to other types of cancer."
Every year, more than 186,000 men in the United States are newly diagnosed with prostate cancer. The most common types of treatment include surgical removal of some, or all, of the prostate, followed by radiation therapy. More than 30,000 men each year who have had their prostates removed experience recurrence of the cancer. In most of these cases, the disease cannot be localized and treated adequately with conventional treatments; therefore, a systemic treatment that efficiently kills small tumors is needed.
Because tumor cells readily bind with certain peptides, researchers have been able to develop highly specific radiopeptides that bind with tumor cells and treat them using specific therapeutic radioactive substances attached to the radiopeptide. Prostate cancer cells-and many other types of cancer cells-have an overabundance of gastrin-releasing peptide receptors, making the cancer a strong candidate for treatment with radiopeptides.
The study compared two different types of radiopeptides. One group of mice was injected with 213 Bi-DOTA-PESIN, which emits alpha particles that are effective at killing cancer cells. The other group was injected with beta-emitting 177 Lu-DOTA-PESIN, which are also effective in tumor cell-killing, but can also cause damage to nearby healthy cells. Alpha particles are able to kill cancer cells without damaging surrounding healthy tissue. A third group of mice received no treatment.
However, at the maximum tolerated dose, the alpha-emitting 213 Bi-DOTA PESIN was significantly more effective, tripling the survival rate of the mice that received the therapy. The results indicate that the alpha-emitting radiopeptide could provide a new approach for treating prostate cancer and eventually other types of cancer.
Society of Nuclear Medicine
Every year, more than 186,000 men in the United States are newly diagnosed with prostate cancer. The most common types of treatment include surgical removal of some, or all, of the prostate, followed by radiation therapy. More than 30,000 men each year who have had their prostates removed experience recurrence of the cancer. In most of these cases, the disease cannot be localized and treated adequately with conventional treatments; therefore, a systemic treatment that efficiently kills small tumors is needed.
Because tumor cells readily bind with certain peptides, researchers have been able to develop highly specific radiopeptides that bind with tumor cells and treat them using specific therapeutic radioactive substances attached to the radiopeptide. Prostate cancer cells-and many other types of cancer cells-have an overabundance of gastrin-releasing peptide receptors, making the cancer a strong candidate for treatment with radiopeptides.
The study compared two different types of radiopeptides. One group of mice was injected with 213 Bi-DOTA-PESIN, which emits alpha particles that are effective at killing cancer cells. The other group was injected with beta-emitting 177 Lu-DOTA-PESIN, which are also effective in tumor cell-killing, but can also cause damage to nearby healthy cells. Alpha particles are able to kill cancer cells without damaging surrounding healthy tissue. A third group of mice received no treatment.
However, at the maximum tolerated dose, the alpha-emitting 213 Bi-DOTA PESIN was significantly more effective, tripling the survival rate of the mice that received the therapy. The results indicate that the alpha-emitting radiopeptide could provide a new approach for treating prostate cancer and eventually other types of cancer.
Society of Nuclear Medicine
Prostate Cancer Current Events and Prostate Cancer News RSSDoes prostate-specific antigen velocity help in early detection prostate cancer?
The November issue of European Urology, the official journal of the European Association of Urology, features an article focussing on prostate specific antigen (PSA) velocity and early cancer detection. It has been suggested that changes in PSA over time aid prostate cancer detection.
New Synthetic Molecules Trigger Immune Response to HIV and Prostate Cancer
Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases.
Chemo-radiation before prostate removal may prevent cancer recurrence
Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival.
Blood vessels might predict prostate cancer behavior
A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?
Short-term hormone therapy and intermediate dose radiation increases survivial for early stage prostate cancer
Short-term hormone therapy given prior to and during intermediate dose radiation treatment for men with early stage prostate cancer increases their chance of living longer, compared to those who receive the same radiation alone.
Task force develops new radiation guidelines for brachytherapy
Radiation dose delivered to the prostate and nearby organs in every brachytherapy procedure should be carefully analyzed using post-implant CT or MRI and uniformly documented in every patient.
1 disease, not 1 demographic
The Asian continent has nearly four billion people living in 47 different countries, and each of these groups has their own unique set of health issues. But when they come to the United States, they're often lumped into one large demographic: "Asian/Pacific Islander."
Cancer survivors may not be getting the help they need to stop smoking
More than a quarter of cancer survivors who still smoke have not been advised to quit smoking by their health care providers in the last year, according to a study published by researchers at Fox Chase Cancer Center in the current issue of the Journal of General Internal Medicine.
Experts issue call to reconsider screening for breast cancer and prostate cancer
Twenty years of screening for breast and prostate cancer - the most diagnosed cancer for women and men - have not brought the anticipated decline in deaths from these diseases, argue experts from the University of California, San Francisco and the University of Texas Health Science Center at San Antonio in an opinion piece published in the "Journal of the American Medical Association."
Detecting the undetectable in prostate cancer screening
A team of Northwestern University researchers, using an extremely sensitive tool based on nanotechnology, has detected previously undetectable levels of prostate-specific antigen (PSA) in patients who have undergone radical prostatectomy.
More Prostate Cancer Current Events and Prostate Cancer News Articles
 |
Dr. Patrick Walsh's Guide to Surviving Prostate Cancer, Second Edition by Patrick C. Walsh (Author), Janet Farrar Worthington (Author) EVERY MAN NEEDS THIS BOOK! Each year, more than 200,00 American men are diagnosed with prostate cancer. The good news is that more men are being cured of this disease than ever before. Now in a revised second edition, this lifesaving guide by Dr. Patrick Walsh and ard-winning science writer Janet Farrar Worthington offers a message of hope to every man facing this illness. Prostate cancer is a different disease in every man--which means that the right treatment varies for each man. Giving you a second opinion from the world's top experts in surgery, pathology, urology, and radiation and medical oncology, this book helps you determine the best plan for you. Learn:What causes prostate cancer--your risk factors, including heredity, diet, and environmentHow some simple changes in your... |
 |
You Can Beat Prostate Cancer by Robert J. Marckini (Author) The task of choosing the right prostate cancer treatment is daunting. It is further complicated by conflicting information the patient receives from physicians and the Internet. This book is written by a prostate cancer survivor who now runs an international prostate cancer support group. It's about his journey and the important things he learned along the way. It is the book the author wishes had been available when he was diagnosed 6 years ago. It is intended to provide specific information for men who are at risk or have been recently diagnosed with prostate cancer. All major treatment options are examined and the pros and cons of each are summarized. A relatively new, non-invasive, highly effective treatment is highlighted. It is an option that cures cancer as well as any other... |
 |
How We Survived Prostate Cancer: What We Did and What We Should Have Done by Victoria Hallerman (Author), Peter S. Albert M.D. (Foreword) Finally, a much-needed voice for the spouses and partners of prostate cancer survivors--an unflinchingly honest and beautifully written memoir about one couple's struggles and transformation that serves as a guide for others dealing with the disease. Facts: Though many sources exist for men dealing with this dreaded disease, their partners are often left on their own to figure out how to deal with personality changes and sudden "male menopause," how to redefine love and intimacy, and how to deal with side effects of the treatment. Victoria Hallerman, an accomplished... |
 |
The Cleveland Clinic Guide to Prostate Cancer (Cleveland Clinic Guides) by Eric Klein (Author) Expert medical advice from one of the nation’s top-ranked hospitals for urology and cancer care
This year, more than 230,000 men will be diagnosed with prostate cancer, while 1 in 6 men will fight prostate cancer in their lives. Prostate cancer is the most common cancer in men over age 50.
In The Cleveland Clinic Guide to Prostate Cancer, Dr. Eric A. Klein, ranked one of America’s best doctors, offers men the substantive information they need to prevent, treat, and even live well with prostate cancer. This excellent resource gives readers the trusted medical guidance Dr. Klein offers his patients, including:
* The best diagnostic tests, new therapies, and medications currently being tested in clinical trials * Insight into the treatments that have been shown... |
 |
A Primer on Prostate Cancer: The Empowered Patient's Guide by Stephen Strum (Author), Donna L. Pogliano (Author) ¡§A Primer on Prostate Cancer, The Empowered Patient¡¦s Guide¡¨ is a basic resource to be used by patients and physicians when there has been a diagnosis of prostate cancer. It outlines a strategy of disease management that is designed to maximize outcomes for the patient and his loved ones. All aspects of diagnosis and testing are discussed; all currently approved treatments for prostate cancer are described. Discussion of treatment options includes information on side effects and includes questions the patient may not think to ask his doctor. Discussions of various treatments include the salvage therapies that might be employed if primary treatment fails. There is an extensive section on the theory and practice of androgen deprivation therapy in it¡¦s various forms, since... |
 |
Surviving Prostate Cancer: What You Need to Know to Make Informed Decisions (Yale University Press Health & Wellness) by E. Fuller Torrey M.D. (Author), Carlton Stoiber (Illustrator) When Dr. E. Fuller Torrey was diagnosed with prostate cancer, none of the books he could find was current enough or comprehensive enough to satisfy his need for information. This book is for the hundreds of thousands of other men who each year receive the same frightening diagnosis. It is the book Dr. Torrey wished he had when he was facing the countless questions that a man with prostate cancer, and his family and friends, all confront. Complete, up-to-date, and readable, the book explains how to come to terms with the diagnosis of prostate cancer, evaluate the severity of the disease, and assess the variety of treatment options and their complications. Many chapters provide information other books barely consider, such as a full discussion of the causes of prostate cancer and an... |
 |
Surviving Prostate Cancer Without Surgery by Bradley Hennenfent (Author) The niche bestseller "Surviving Prostate Cancer Without Surgery" begins with the shooting of a urologist and includes a World War II Battle. The book exposes the big lie about radical prostate surgery, is filled with cartoons and simple diagrams, and is written for the average layperson in easy-to-understand style. "Surviving Prostate Cancer Without Surgery" quotes Dr. Gary Onik, M.D., Cryosurgeon and Director of Surgical Imaging at Celebration Health Hospital, Celebration, Florida, who says: "I expect that within five years we will see the death of the radical prostatectomy as a treatment for prostate cancer." The author, Bradley Hennenfent, M.D., has seen five uncles suffer from prostate cancer and his book includes many uplifting stories about less harmful treatments than surgery. Dr.... |
 |
Prostate Cancer for Dummies by Paul H. Lange (Author), Christine Adamec (Author), Christine Adamec (Author) Hearing that you have prostate cancer, or even that you may have it, is very scary. But this disease, in many cases, is curable. Even if you have advanced cancer that's spread beyond the prostate, many treatments help extend your life for years. You need good information to help you with the decisions that lie ahead, and this book provides you with this information. Prostate Cancer For Dummies can help you if You have prostate cancer (or you think that you have it), or someone close to you has it. You want information on treatments for prostate cancer as you form a treatment plan with your doctor. You are curious about alternative therapies for prostate cancer. You want to know what actions you can take over the long-term to continue to fight your... |
 |
Eat to Beat Prostate Cancer Cookbook by David Ricketts (Author) Prostate cancer is now the most common nonskin cancer among men in the United States. In 2005 alone, 250,000 new cases were diagnosed, and that number is certain to rise with each passing year. No one is more aware of this than David Ricketts, experienced cookbook author and recent prostate cancer survivor. Shortly after surgery and radiation treatments, Ricketts began to research food and lifestyle changes that might inhibit the likelihood of prostate cancer as well as its progression. The result is this uniquely specific cookbook, which takes full advantage of foods thought to fight prostate cancer while eliminating those believed to contribute to the disease. Eat to Beat Prostate Cancer Cookbook features more than 200 delicious recipes for everything from snacks, sandwiches,... |
 |
Prostate and Cancer: A Family Guide to Diagnosis, Treatment, and Survival by Sheldon Marks MD (Author) Prostate cancer is one of the most common cancers affecting American men, with over 186,000 new cases diagnosed in the United States annually; 1 in 6 men will be diagnosed with prostate cancer during his lifetime. Renowned prostate cancer specialist Sheldon Marks offers the definitive guide for men concerned about or diagnosed with prostate cancer, and for their families. Since the third edition (2003), there have been significant changes in treatment and resources. Working with Dr. Judd Moul, the Chairman of Urology at Duke and one of the world’s top experts on prostate cancer, Marks provides the most up-to- date information on diagnosis, treatment, and common questions. |
| © 2009 BrightSurf.com |